Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils

Shinji Okada, John B. Hagan, Masahiko Kato, Jennifer L. Bankers-Fulbright, Loren W. Hunt, Gerald J. Gleich, Hirohito Kita

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Eosinophils and cytokines active on eosinophils, especially IL-5, are believed to be critically involved in chronic allergic diseases. IL-5 activates eosinophils and enhances their survival in vitro by delaying apoptosis. In this study, we found that lidocaine and six analogues blunt responses of eosinophils to IL-5. Lidocaine and its derivatives inhibit IL- 5-mediated eosinophil survival in a concentration-dependent manner (IC50 = 110 μM for 30 pg/ml IL-5). At suboptimal lidocaine concentrations, the eosinophil survival response to IL-5 shifts and more IL-5 is required to maintain survival. The inhibitory effect requires at least 24-h exposure of eosinophils to lidocaine, and the protein kinase C activator, PMA, completely reverses the inhibition. A multiparameter flow-cytometric analysis shows that lidocaine hastens the apoptosis of eosinophils normally delayed by IL-5. Lidocaine does not affect IL-5R expression or IL-5-induced protein tyrosine phosphorylation. Lidocaine also inhibits eosinophil survival mediated by IL- 3 or granulocyte-macrophage CSF, although less potently than that mediated by IL-5. Furthermore, lidocaine inhibits eosinophil superoxide production stimulated by IL-5, granulocyte-macrophage CSF, or IL-3, but not that stimulated by platelet-activating factor, immobilized IgG, or PMA. Lidocaine and its derivatives show novel immunomodulatory properties and are able to blunt eosinophil responses to cytokines in addition to their local anesthetic or antiarrhythmic properties. Thus, lidocaine and its derivatives may represent a new class of therapeutic agents to treat patients with allergic diseases.

Original languageEnglish (US)
Pages (from-to)4010-4017
Number of pages8
JournalJournal of Immunology
Volume160
Issue number8
StatePublished - Apr 15 1998

Fingerprint

Interleukin-5
Lidocaine
Eosinophils
Survival
Interleukin-3
Granulocytes
Macrophages
Apoptosis
Cytokines
Platelet Activating Factor
Local Anesthetics
Superoxides
Protein Kinase C
Inhibitory Concentration 50
Tyrosine
Chronic Disease
Immunoglobulin G
Phosphorylation

ASJC Scopus subject areas

  • Immunology

Cite this

Okada, S., Hagan, J. B., Kato, M., Bankers-Fulbright, J. L., Hunt, L. W., Gleich, G. J., & Kita, H. (1998). Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. Journal of Immunology, 160(8), 4010-4017.

Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. / Okada, Shinji; Hagan, John B.; Kato, Masahiko; Bankers-Fulbright, Jennifer L.; Hunt, Loren W.; Gleich, Gerald J.; Kita, Hirohito.

In: Journal of Immunology, Vol. 160, No. 8, 15.04.1998, p. 4010-4017.

Research output: Contribution to journalArticle

Okada, S, Hagan, JB, Kato, M, Bankers-Fulbright, JL, Hunt, LW, Gleich, GJ & Kita, H 1998, 'Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils', Journal of Immunology, vol. 160, no. 8, pp. 4010-4017.
Okada S, Hagan JB, Kato M, Bankers-Fulbright JL, Hunt LW, Gleich GJ et al. Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. Journal of Immunology. 1998 Apr 15;160(8):4010-4017.
Okada, Shinji ; Hagan, John B. ; Kato, Masahiko ; Bankers-Fulbright, Jennifer L. ; Hunt, Loren W. ; Gleich, Gerald J. ; Kita, Hirohito. / Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. In: Journal of Immunology. 1998 ; Vol. 160, No. 8. pp. 4010-4017.
@article{d34f0cb68b864999b6708457834b90e6,
title = "Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils",
abstract = "Eosinophils and cytokines active on eosinophils, especially IL-5, are believed to be critically involved in chronic allergic diseases. IL-5 activates eosinophils and enhances their survival in vitro by delaying apoptosis. In this study, we found that lidocaine and six analogues blunt responses of eosinophils to IL-5. Lidocaine and its derivatives inhibit IL- 5-mediated eosinophil survival in a concentration-dependent manner (IC50 = 110 μM for 30 pg/ml IL-5). At suboptimal lidocaine concentrations, the eosinophil survival response to IL-5 shifts and more IL-5 is required to maintain survival. The inhibitory effect requires at least 24-h exposure of eosinophils to lidocaine, and the protein kinase C activator, PMA, completely reverses the inhibition. A multiparameter flow-cytometric analysis shows that lidocaine hastens the apoptosis of eosinophils normally delayed by IL-5. Lidocaine does not affect IL-5R expression or IL-5-induced protein tyrosine phosphorylation. Lidocaine also inhibits eosinophil survival mediated by IL- 3 or granulocyte-macrophage CSF, although less potently than that mediated by IL-5. Furthermore, lidocaine inhibits eosinophil superoxide production stimulated by IL-5, granulocyte-macrophage CSF, or IL-3, but not that stimulated by platelet-activating factor, immobilized IgG, or PMA. Lidocaine and its derivatives show novel immunomodulatory properties and are able to blunt eosinophil responses to cytokines in addition to their local anesthetic or antiarrhythmic properties. Thus, lidocaine and its derivatives may represent a new class of therapeutic agents to treat patients with allergic diseases.",
author = "Shinji Okada and Hagan, {John B.} and Masahiko Kato and Bankers-Fulbright, {Jennifer L.} and Hunt, {Loren W.} and Gleich, {Gerald J.} and Hirohito Kita",
year = "1998",
month = "4",
day = "15",
language = "English (US)",
volume = "160",
pages = "4010--4017",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "8",

}

TY - JOUR

T1 - Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils

AU - Okada, Shinji

AU - Hagan, John B.

AU - Kato, Masahiko

AU - Bankers-Fulbright, Jennifer L.

AU - Hunt, Loren W.

AU - Gleich, Gerald J.

AU - Kita, Hirohito

PY - 1998/4/15

Y1 - 1998/4/15

N2 - Eosinophils and cytokines active on eosinophils, especially IL-5, are believed to be critically involved in chronic allergic diseases. IL-5 activates eosinophils and enhances their survival in vitro by delaying apoptosis. In this study, we found that lidocaine and six analogues blunt responses of eosinophils to IL-5. Lidocaine and its derivatives inhibit IL- 5-mediated eosinophil survival in a concentration-dependent manner (IC50 = 110 μM for 30 pg/ml IL-5). At suboptimal lidocaine concentrations, the eosinophil survival response to IL-5 shifts and more IL-5 is required to maintain survival. The inhibitory effect requires at least 24-h exposure of eosinophils to lidocaine, and the protein kinase C activator, PMA, completely reverses the inhibition. A multiparameter flow-cytometric analysis shows that lidocaine hastens the apoptosis of eosinophils normally delayed by IL-5. Lidocaine does not affect IL-5R expression or IL-5-induced protein tyrosine phosphorylation. Lidocaine also inhibits eosinophil survival mediated by IL- 3 or granulocyte-macrophage CSF, although less potently than that mediated by IL-5. Furthermore, lidocaine inhibits eosinophil superoxide production stimulated by IL-5, granulocyte-macrophage CSF, or IL-3, but not that stimulated by platelet-activating factor, immobilized IgG, or PMA. Lidocaine and its derivatives show novel immunomodulatory properties and are able to blunt eosinophil responses to cytokines in addition to their local anesthetic or antiarrhythmic properties. Thus, lidocaine and its derivatives may represent a new class of therapeutic agents to treat patients with allergic diseases.

AB - Eosinophils and cytokines active on eosinophils, especially IL-5, are believed to be critically involved in chronic allergic diseases. IL-5 activates eosinophils and enhances their survival in vitro by delaying apoptosis. In this study, we found that lidocaine and six analogues blunt responses of eosinophils to IL-5. Lidocaine and its derivatives inhibit IL- 5-mediated eosinophil survival in a concentration-dependent manner (IC50 = 110 μM for 30 pg/ml IL-5). At suboptimal lidocaine concentrations, the eosinophil survival response to IL-5 shifts and more IL-5 is required to maintain survival. The inhibitory effect requires at least 24-h exposure of eosinophils to lidocaine, and the protein kinase C activator, PMA, completely reverses the inhibition. A multiparameter flow-cytometric analysis shows that lidocaine hastens the apoptosis of eosinophils normally delayed by IL-5. Lidocaine does not affect IL-5R expression or IL-5-induced protein tyrosine phosphorylation. Lidocaine also inhibits eosinophil survival mediated by IL- 3 or granulocyte-macrophage CSF, although less potently than that mediated by IL-5. Furthermore, lidocaine inhibits eosinophil superoxide production stimulated by IL-5, granulocyte-macrophage CSF, or IL-3, but not that stimulated by platelet-activating factor, immobilized IgG, or PMA. Lidocaine and its derivatives show novel immunomodulatory properties and are able to blunt eosinophil responses to cytokines in addition to their local anesthetic or antiarrhythmic properties. Thus, lidocaine and its derivatives may represent a new class of therapeutic agents to treat patients with allergic diseases.

UR - http://www.scopus.com/inward/record.url?scp=0032522838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032522838&partnerID=8YFLogxK

M3 - Article

C2 - 9558110

AN - SCOPUS:0032522838

VL - 160

SP - 4010

EP - 4017

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 8

ER -